A Systematic Review and Meta-Analysis of Serologic Response following Coronavirus Disease 2019 (COVID-19) Vaccination in Solid Organ Transplant Recipients고형장기이식 수혜자의 코로나19(COVID-19) 백신접종 후 혈청학적 반응에 대한 체계적인 검토 및 메타분석Meta-Analysis Published on 2022-08-192022-09-12 Journal: Viruses [Category] 진단, [키워드] 95% CI analyzed BNT162b2 booster dose conducted controls coronavirus disease COVID-19 COVID-19 vaccination COVID-19 vaccine database develop dose doses evaluate greater heart transplant identify Immunocompromised kidney kidney transplant lung lung transplant Meta-analysis monoclonal antibody MOST mRNA vaccination mRNA vaccine mRNA-1273 observational study organ Organ transplant outcomes Patient patient population Prophylaxis proportion recipient recipients remained reported response review risk serologic Serologic response Solid solid organ transplant SOT SOT patient subset the vaccine Transplant vaccination Vaccinations Vaccine vaccine. [DOI] 10.3390/v14081822 PMC 바로가기 [Article Type] Meta-Analysis
Mycophenolate mofetil decreases humoral responses to three doses of SARS-CoV-2 vaccine in liver transplant recipientsMycophenolate mofetil은 간 이식 수혜자의 SARS-CoV-2 백신 3회 투여에 대한 체액 반응을 감소시킵니다.Article Published on 2022-08-012022-09-11 Journal: Liver international : official journal of the Inte [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] 95%CI Analysis anti-SARS-CoV-2 anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody anti-SARS-CoV-2 vaccination antibody Antibody titre appear booster dose consultation decrease defined determine develop dose doses Efficacy enrolled Factor failure French Gender humoral Humoral response identify independent independent risk factor liver liver transplant male MMF mRNA mRNA vaccine mycophenolate mycophenolate mofetil mycophenolate mofetil. Patient patients Predictive receiving recipient recipients responders response rate response to vaccination responsiveness risk factor Risk factors SARS-CoV-2 SARS-CoV-2 vaccine Serious Adverse Events Seroconversion Serologic response solid organ solid organ transplant the patient the vaccine Treatment vaccination Vaccine [DOI] 10.1111/liv.15258 PMC 바로가기 [Article Type] Article
Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy면역억제 요법을 받는 환자에서 표준 및 3차 접종 SARS-CoV-2 백신 접종의 면역원성과 안전성Observational Study Published on 2022-08-012022-09-12 Journal: Arthritis & rheumatology (Hoboken, N.J.) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] Adult patient adverse event age antibody arbitrary unit characterized combination therapy comparable Control controls defined disease dose evaluate facilitate full-length healthy healthy control healthy controls IgG antibody Immune-mediated inflammatory disease immunogenicity immunosuppressive inhibitor interquartile range jak inhibitors lowest median Necrosis Patient patient group patients performed predictor proportion prospective observational study psoriatic arthritis RBD receiving regimen Responder responders rheumatoid arthritis risk RNA-1273 Safe Safety safety profile SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine Serologic response Spike protein spondyloarthritis Standard Support the receptor-binding domain the SARS-CoV-2 therapy ulcerative colitis vaccination Vaccine vaccine dose vaccine response [DOI] 10.1002/art.42153 PMC 바로가기 [Article Type] Observational Study
Antibody response to the messenger RNA-1273 vaccine (Moderna) in liver transplant recipients간 이식 환자에서 메신저 RNA-1273 백신(모더나)에 대한 항체 반응Article Published on 2022-07-012022-09-12 Journal: Hepatology communications [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Administered anti-S anti-S IgG antibody cause clinical coronavirus coronavirus disease COVID-19 COVID-19 infection develop dose evaluated examined Factor first vaccination Follow-up General population Hepatitis IgG Immunoglobulin Immunological response immunosuppressive include interquartile range laboratory data liver Liver transplantation Logistic regression LTR LTRs median median age men Messenger RNA Moderna MOST Most patient mRNA mRNA-1273 vaccine mRNA-based vaccine Odds ratio Patient positive predict receiving recipient recipients regimen response RNA-1273 SARS-CoV-2 Serologic response shown tested the spike protein the vaccine university Vaccine vaccine dose [DOI] 10.1002/hep4.1937 PMC 바로가기 [Article Type] Article
Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma요로상피 및 신세포암 환자에서 SARS-CoV-2 BNT162b2 백신에 대한 혈청학적 반응에 대한 활성 항암 요법의 효과Article Published on 2022-07-012022-09-12 Journal: International journal of urology : official journa [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome adverse events Antibody Response Antibody titer anticancer blood sample BNT162b2 BNT162b2 vaccine Cell control group coronavirus defined dose Effect evaluate evaluated exhibited Factor group groups healthy control Immunoglobulin Logistic regression analysis metastatic disease mRNA mRNA vaccine not significantly different Older age Patient patients renal renal cell carcinoma SARS-CoV-2 SARS-CoV-2 BNT162b2 Serologic response seropositive Seropositivity significantly spike receptor-binding domain steroid treatment the patient therapy Treatment university urothelial carcinoma. vaccination Vaccine [DOI] 10.1111/iju.14882 PMC 바로가기 [Article Type] Article
Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis질병 조절 요법 후 다발성 경화증 환자에서 COVID-19 예방 접종의 반응: 메타 분석Meta-Analysis Published on 2022-07-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), SARS, 바이오마커, 유전자 메커니즘, [키워드] addressed anti-CD20 anti-CD20 therapy anti-CD20 treatment association benefit booster dose CD20 cellular response Cochrane Library conducted COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines Disease-modifying therapies Efficacy evaluate foundation humoral Humoral response IFN-β immune response literature medRxiv Meta-analysis Multiple multiple sclerosis multiple sclerosis. natural no significant difference Odds ratio Odds ratios other treatment other treatments Patient random-effect receiving receptor required response response to vaccination risk SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines Science Serologic response serological Shanghai significantly higher sphingosine sphingosine-1-phosphate suggested supported T-cell Response therapy Treatment vaccination was performed [DOI] 10.1016/j.ebiom.2022.104102 PMC 바로가기 [Article Type] Meta-Analysis
Evaluation of the Correlation Between Responders and Non-Responders to the Second Coronavirus Disease Vaccination In Kidney Transplant Recipients: A Retrospective Single-Center Cohort StudyArticle Published on 2022-07-012022-11-15 Journal: Transplantation proceedings [Category] COVID19(2023년), SARS, 진단, [키워드] anti-SARS-CoV-2 IgG Antibody Response Antibody titer cofactor cohort study COVID-19 vaccination COVID-19 vaccine dosage dose evaluated Follow-up group groups healthy controls IgG level immune response Immunoglobulin kidney transplant kinetics of antibody median time Messenger RNA no significant difference Pfizer-BioNTech receiving recipient recipients retrospective SARS-CoV-2 second second dose second vaccination Serologic response significantly lower single-center the SARS-CoV-2 to define Transplant treated Vaccine [DOI] 10.1016/j.transproceed.2022.05.002 PMC 바로가기
Humoral Response to the Third Dose of Sars-Cov-2 Vaccine in Kidney Transplant RecipientsArticle Published on 2022-07-012022-11-15 Journal: Transplantation proceedings [Category] COVID19(2023년), SARS, 진단, [키워드] administration analyzed anti-S antibody Antibody titers BNT162b2 mRNA vaccine BNT162b2 vaccine booster CD4 Cellular immune response Control correlated Decreased develop Donor dose doses Factors health care workers humoral IgG immune response in both groups increase in individual intracellular cytokine kidney kidney transplant recipients Lymphocyte count mononuclear cells MOST mRNA Older age Peripheral blood recipient required response Safe SARS-CoV-2 vaccine Serologic response seronegative seropositive significant increase significantly solid organ transplant TNFα Transplant [DOI] 10.1016/j.transproceed.2022.02.011 PMC 바로가기
Serologic response to a third dose of an mRNA-based SARS-CoV-2 vaccine in lung transplant recipients폐 이식 환자에서 mRNA 기반 SARS-CoV-2 백신 3차 접종에 대한 혈청학적 반응Article Published on 2022-06-012022-09-12 Journal: Transplant immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome binding complement coronavirus COVID-19 cut-off value develop dose Factor Immune status IMPROVE increased risk Infection lectin pathway lung transplant mRNA-based mRNA-based SARS-CoV-2 vaccine parameters Patient positive Prednisone Previous studies recipient recipients SARS-CoV-2 SARS-CoV-2 vaccine serologic Serologic response serological response serum IgG severe coronavirus disease significantly significantly higher solid organ transplant vaccination Vaccination response. vaccine dose was measured [DOI] 10.1016/j.trim.2022.101599 PMC 바로가기 [Article Type] Article
Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age6~11세 어린이의 mRNA-1273 Covid-19 백신 평가Clinical Trial Published on 2022-05-112022-09-25 Journal: The New England Journal of Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료법, [키워드] 95% CI 95% confidence interval acute respiratory syndrome Administered Adults age Analysis assigned authority B.1.617.2 children circulating coronavirus coronavirus disease criterion development dominant dose effective Efficacy Estimated events fatigue groups headache immune response incidence Infection Inflammatory injection Injection-site pain Interim interquartile range median mRNA-1273 mRNA-1273 vaccine myocarditis Neutralizing antibody titer observer-blinded open label Part participant phase 2–3 trial phase 3 trial Placebo placebo-controlled Prevent public health Randomly receive reported response Result Safe Secondary objective selected Serious Adverse Events Serologic response Symptoms syndrome the vaccine transient adverse Trial Vaccine variant was selected Year [DOI] 10.1056/NEJMoa2203315 PMC 바로가기 [Article Type] Clinical Trial